Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.
Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.
复制标题
在旧金山湾区接受血液透析的患者中,金黄色葡萄球菌定植率较低,万古霉素敏感性降低。
DOI:
10.1086/429906
复制
发表时间:
2005
期刊:
影响因子:
--
通讯作者:
Chambers,HenryF
中科院分区:
文献类型:
--
作者:
Eguia,JoseM;Liu,Catherine;Moore,Matthew;Wrone,ElizabethM;Pont,Joan;Gerberding,JulieL;Chambers,HenryF
BackgroundStaphylococcus aureusexhibits varying degrees of reduced vancomycin susceptibility, and strains with intermediate levels of resistance are thought to emerge by antibiotic selection of subpopulations in heterogeneously resistant precursor strains exposed to this antibiotic. We sought to determine the prevalence of and risk factors for carriage of potential heterogeneous vancomycin-intermediateS. aureus(hVISA).MethodsWe prospectively observed a cohort of 211 patients undergoing hemodialysis and performed quarterly surveillance cultures for up to 2 years. We screened for reduced vancomycin susceptibility using brain-heart infusion agar with 4 µg/mL vancomycin.ResultsWe identified 10 colonizing potential hVISA isolates recovered from 7 patients among both methicillin-susceptible and methicillin-resistantS. aureusstrains. No confirmed hVISA isolates were identified; we can be 95% certain that the prevalence of confirmed hVISA carriage does not exceed 1.4%. When compared with noncolonized hemodialysis patients, neither vancomycin exposure, duration of hospitalization, nor any baseline clinical or demographic factor was found to predict colonization with potential hVISA on univariate analyses; increased number of months receiving hemodialysis was associated with potential hVISA colonization on multivariate analysis.ConclusionsDespite numerous published reports ofS. aureuswith reduced vancomycin susceptibility, carriage of these isolates remains a rare phenomenon. Given the unclear clinical significance of potential hVISA, it is not clear whether clinical laboratories should identify such strains, or how they should do so.